Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pandemic Flu H5 mRNA Vaccine in Healthy Adults
NCT06727058Phase 2Completed
- Sponsor
- Sanofi
- Start
- Dec 2024
- Primary completion
- Mar 2026
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of flu pandemic mRNA vaccine in influenza (4 arms), sponsored by Sanofi. Primary endpoints: Presence of immediate adverse events at 30 minutes, Presence of solicited injection site reactions at 7 days and 6 more. Started Dec 2024; status: completed.
02
Drugs
flu pandemic mRNA vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT06727058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06727058.